Parkinson’s Disease Drugs Market: Launch of Safe and Effective Disease-modifying Drugs (DMD) to Drive Growth Prospects

0
124
Parkinsons Disease (PD) Drugs Market

MarketResearchReports.biz has recently added a new market study to its repository, titled “Global Parkinsons Disease (PD) Drugs Market 2017-2021.” According to the report, the global Parkinson’s disease drugs market is anticipated to expand at a 4% CAGR between 2017 and 2021. According to the lead author of this report, the launch of effective and safe disease-modifying drugs (DMD) will give much impetus to the Parkinson disease drugs market. The introduction of disease modifying drugs has the capability of changing the treatment strategy as they modify the progression of the disease and this is boosting the growth of the global Parkinson’s disease drugs market.

As the treatment of Parkinson’s disease involves therapies that can treat neurodegenerative disorders and offer symptomatic relief to patients, but these therapies do not treat the underlying cause of the disease, the demand for DMD is increasing. As DMD helps avoid the prolonging of treatment duration for Parkinson’s disease, it will be in much demand.

One of the key trends in the global Parkinson’s disease drugs market is the introduction of gene therapy. Gene therapy reverses the progression of Parkinson’s disease and will be a trend that will continue to gain traction throughout the forecast period. The demand for gene therapy is also increasing because gene transfer to the brain cells which are damaged can help improve the motor functions by making use of viral vector technology. Additionally gene therapy can prevent the progression of the Parkinson’s disease by understanding the genetic origin of PD and result in the transfer of the neuroprotective gene into the basal ganglia and nuclei of the brain.

For Sample Copy, click here:  https://www.marketresearchreports.biz/sample/sample/1307160

The global Parkinson’s disease drugs market is highly fragmented on account of the presence of small and large players. However, this also makes the market very competitive. Vendors are increasingly focusing on various forms of partnership, collaborations, mergers and acquisitions so as to strengthen their foothold in the market. Market players are also focusing on spreading the awareness about Parkinson’s disease.

On the basis of drug class, the market is segmented into dopamine agonist, glutamate inhibitors, monoamine oxidase inhibitors, and acetylcholinesterase inhibitors. Of these, dopamine agonist is the segment which is leading in the market. dopamine agonist treats the central nervous system disorders which are caused by hypodopaminergic conditions. Dopamine agonists directly activate the postsynaptic dopamine receptors. The increased therapeutic benefits of Parkinson disease and dopamine drug class is driving an increasing number of doctors to prescribe this drug for Parkinson’s disease. This segment will continue to witness high growth as dopamine agonist improves the motor functions of a patient suffering from early stage Parkinson’s disease  and also reduces the risk of motor fluctuations and dyskinesia.

On the basis of Geography the Global Parkinson’s disease drugs market is segmented into Asia Pacific Europe the Middle East and Africa and the Americas. According to the report, in 2016 the Americas dominated in the Parkinson’s disease drugs market, thanks to the expanding geriatric population and high incidences of Parkinson’s disease. In addition to this, the Americas Parkinson’s disease drugs market is benefiting from the favorable healthcare coverage and insurance systems and Medicare which is allowing the patient pool to easily access effective treatment for Parkinson’s disease. Moreover, the increased exploration by market players towards novel anti Parkinson’s drugs such as BIIB054 from Biogen will bolster the growth of the market in the Americas.

Leading players within the market are: Biogen, Abital Pharma, Boehringer Ingelheim, AbbVie, Addex Therapeutics, GlaxoSmithKline, Eisai, H. Lundbeck, Prana Biotechnology, Novartis, F. Hoffmann-La Roche, Otsuka Pharmaceutical, Teva Pharmaceutical Industries

Leave a Reply